Treatment results and prognostic factors of patients with vulvar cancer treated with postoperative or definitive radiotherapy

Basit Öğe Kaydı
dc.contributor.authorAlanyali, Senem
dc.contributor.authorDuran, Ozge
dc.contributor.authorOzsaran, Zeynep
dc.contributor.authorOzsaran, Aydin
dc.contributor.authorAkman, Levent
dc.contributor.authorSolmaz, Ulas
dc.contributor.authorGokcu, Mehmet
dc.contributor.authorSanci, Muzaffer
dc.contributor.authorAras, Arif B.
dc.date.accessioned2019-10-27T23:09:57Z
dc.date.available2019-10-27T23:09:57Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractPurpose: Vulvar cancer is a relatively uncommon type of gynecologic cancer. The aim of this study is to analyze the treatment results and prognostic factors of vulvar cancer. Methods: Forty-four vulvar cancer patients treated between 2000 and 2011 at the Department of Radiation Oncology, Ege University Faculty of Medicine, were retrospectively reviewed. External radiotherapy (RT) was applied with 6-18 MV linear accelerators with 1.8 Gy daily fractions with a median total dose of 50.4 Gy (45-59.4 Gy) for postoperative cases and 64.8 Gy (range 54-66 Gy) for definitive cases. Statistical analyses were performed with SPSS 13.0. Results: Among 44 patients with a median age of 68 years (range 28-86), 14 (31.8%) were treated with curative and 30 (68.2%) were treated with postoperative RT or radiochemotherapy (RCT). According to International Federation of Gynecology and Obstetrics staging, 11 (25%) had stage IB, 10 (22.7%) had stage II, 6 (13.6%) had stage IIIA, 5 (11.4%) had stage IIIB, and 12 (27.3%) had stage IVA disease. Within a median of 24 months (range 6-135) of followup, 11 (27.3%) patients had local recurrence, 8 had regional recurrence, 2 had both local and regional recurrence, and 6 had distant metastases. Five-year locoregional, disease-free, and overall survival rates were 45%, 40%, and 54%, respectively. Older age, poor tumor differentiation, positive surgical margin, and lymphovascular space invasion were found to be important prognostic factors for disease-related outcomes. Conclusions: Prognosis of vulvar cancer remains poor even with a multidisciplinary approach. Molecular prognostic factors need to be defined for individualized treatment options to achieve better treatment results.en_US
dc.identifier.doi10.5301/tj.5000509en_US
dc.identifier.endpage315en_US
dc.identifier.issn0300-8916
dc.identifier.issn2038-2529
dc.identifier.issue3en_US
dc.identifier.pmid27079905en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage311en_US
dc.identifier.urihttps://doi.org/10.5301/tj.5000509
dc.identifier.urihttps://hdl.handle.net/11454/52785
dc.identifier.volume102en_US
dc.identifier.wosWOS:000380955900014en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofTumori Jen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPrognostic factorsen_US
dc.subjectRadiotherapyen_US
dc.subjectSurgeryen_US
dc.subjectVulvar canceren_US
dc.titleTreatment results and prognostic factors of patients with vulvar cancer treated with postoperative or definitive radiotherapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu